Core Viewpoint - Lucid Diagnostics has partnered with Hoag to enhance access to EsoGuard esophageal precancer testing, aiming to combat the rising incidence of esophageal cancer in Orange County [1][2]. Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3]. - The EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients, performed through a non-invasive office procedure [3]. Partnership Details - Hoag has launched a comprehensive esophageal precancer testing program using Lucid's EsoGuard test, integrating it into its digestive health, primary care, and concierge medicine programs [1]. - The partnership is seen as a significant milestone in expanding access to EsoGuard within large healthcare systems, with expectations that it will serve as a model for other health systems [2]. Industry Context - The incidence of esophageal cancer has increased tenfold over the past four decades, highlighting the need for effective screening methods [2]. - The EsoGuard test offers a 3-minute non-endoscopic procedure aimed at identifying at-risk patients, which is critical for early intervention and potentially saving lives [2]. Hoag Overview - Hoag is a nonprofit regional healthcare delivery system in Orange County, California, recognized for its comprehensive personalized care and consisting of 1,800 physicians, 17 urgent care facilities, and two award-winning hospitals [5]. - It is ranked as the highest hospital in Orange County by U.S. News & World Report and is known for its specialized services in various health areas, including cancer and digestive health [5].

Core Points - Lucid Diagnostics Inc. will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the close of U.S. equity markets on June 27, 2025, as part of the 2025 annual reconstitution [1][2] - This inclusion is expected to enhance Lucid's visibility and access to a broader range of institutional investors, reflecting the company's progress in enhancing shareholder value over the past year [2] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [4] - The company's EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device are the first and only commercially available tools aimed at preventing cancer through early detection of esophageal precancer in at-risk patients [4] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes, indicating the significance of these indices for institutional investors and investment managers [2]

Core Viewpoint - Lucid Diagnostics Inc. has secured capital to extend its operational runway significantly, positioning the company to capitalize on upcoming reimbursement milestones and accelerate commercialization efforts for its EsoGuard product [4][6]. Business Highlights - The company is expanding cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage [4]. - A partnership with a major health system has been established to launch a comprehensive EsoGuard esophageal precancer testing program, enhancing access for at-risk patients [6]. - The company has launched the "Embrace the Future" campaign to promote its EsoCheck® Cell Collection Device, which features innovative technology compared to traditional methods [6]. - A National Cancer Institute-sponsored study has shown that EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, potentially increasing market opportunity by up to 70% [6]. Financial Results - For the three months ended March 31, 2025, Lucid processed 3,034 EsoGuard tests and recognized $0.8 million in revenue from EsoGuard [6]. - The company reported operating expenses of approximately $13.3 million, including $1.0 million in stock-based compensation, leading to a GAAP net loss of approximately $36.0 million or $(0.52) per share [6][9]. - The non-GAAP adjusted loss for the same period was approximately $11.2 million or $(0.16) per share [7][11]. - As of March 31, 2025, Lucid had cash and cash equivalents of $25.2 million, an increase from $22.4 million as of December 31, 2024, and completed a public offering for net proceeds of $16.1 million [10].

Core Points - Lucid Diagnostics Inc. will host a business update conference call and webcast on May 14, 2025, at 8:30 AM ET to discuss company operations and growth strategy [1] - The call will feature Lishan Aklog, M.D., the CEO, and Dennis McGrath, the CFO, who will present the first quarter 2025 financial results [1] - The conference call can be accessed via telephone or through the company's investor relations website [2] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [4] - Lucid's EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device are the first commercially available tools aimed at early detection of esophageal precancer [4]

Core Insights - Lucid Diagnostics Inc. announced positive data from a National Cancer Institute-sponsored study showing that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer in at-risk patients without GERD symptoms, potentially expanding its market opportunity [1][2][3] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [4] Study Findings - The study enrolled patients without GERD symptoms who met AGA recommendations for Barrett's Esophagus (BE) screening, demonstrating a 100% negative predictive value (NPV) for detecting esophageal precancer [2] - The prevalence of Barrett's Esophagus in the study was found to be 8.4%, comparable to rates in symptomatic GERD patients [2] Market Opportunity - If the ongoing multicenter NIH-sponsored study replicates the promising results, the market opportunity for EsoGuard esophageal precancer testing could increase by as much as 70%, potentially reaching a total of approximately $60 billion [3]

Core Viewpoint - Lucid Diagnostics Inc. has announced a public offering of 12,500,000 shares at a price of $1.20 per share, aiming to raise approximately $15 million for working capital and general corporate purposes [1][2]. Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [6]. Offering Details - The offering includes a 45-day option for underwriters to purchase an additional 1,875,000 shares at the public offering price [1]. - The gross proceeds from the offering are expected to be around $15 million, excluding any proceeds from the underwriters' option [2]. - The offering is expected to close on or about April 11, 2025, subject to customary closing conditions [2]. Underwriters - Canaccord Genuity LLC is acting as the sole bookrunner for the offering, while Maxim Group LLC is serving as co-manager [3]. Regulatory Information - The offering is made pursuant to a shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on December 6, 2022 [4]. - A prospectus supplement will be filed with the SEC, and the securities may only be offered by means of a written prospectus [4].

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [5]. Offering Details - Lucid Diagnostics announced its intention to offer shares of common stock through an underwritten public offering, with plans to grant underwriters a 45-day option to purchase additional shares. Proceeds from the offering are expected to support working capital and general corporate purposes [1]. - Canaccord Genuity LLC is acting as the sole bookrunner for the offering, while Maxim Group LLC is serving as co-manager [2]. Regulatory Information - The offering is being made pursuant to a shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on December 6, 2022. A prospectus supplement will be filed with the SEC [3].

Lucid Diagnostics - Lucid Diagnostics的EsoGuard在2024年第四季度的收入为120万美元[12]，测试量为4042，环比增长45%[12] - Highmark Blue Cross Blue Shield in New York 建立了EsoGuard的积极商业保险覆盖政策[12] - NCCN临床实践指南更新，包括食管癌前病变筛查，与ACG等专业协会指南保持一致[12] Veris Health - 完成了一项私募融资，总收益约为240万美元[16]，Veris普通股的定价为3500万美元的税前估值[16] - 与俄亥俄州立大学詹姆斯癌症医院的试点项目延长至2025年4月[16] Financial Performance - 截至2024年第四季度末，公司持有的现金为118.5万美元[21]，高于第三季度的76.5万美元[21]，增加了42万美元[21] - 2024年第四季度的收入为1万美元[23]，低于2023年第四季度的104.9万美元[23]，减少了103.9万美元[23] - 2024年第四季度的运营费用为519.8万美元[23]，低于2023年第四季度的1743.3万美元[23]，减少了1223.5万美元[23] - 2024年第四季度的净利润为114.2万美元[23]，而2023年第四季度的净亏损为1740.8万美元[23]，增加了1855万美元[23]

Core Insights - The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to invasive endoscopy for detecting esophageal precancer [1][2] Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company focused on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3] - The EsoGuard Esophageal DNA Test is designed for early detection of esophageal precancer in at-risk patients and is performed using the EsoCheck Esophageal Cell Collection Device, which allows for a noninvasive office procedure [3] Industry Impact - The alignment of NCCN Guidelines with multiple gastroenterology society guidelines on Barrett's Esophagus (BE) screening is expected to positively influence commercial insurance policy coverage decisions, thereby expanding access to EsoGuard testing [2]

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [5] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [5]. Recent Offering - Lucid Diagnostics announced subscription agreements to sell 13,939,331 shares of common stock at a price of $1.10 per share, expecting gross proceeds of approximately $15.3 million [1]. - The offering is being managed by Canaccord Genuity as the sole placement agent, with the closing expected around March 5, 2025, subject to customary conditions [2]. Use of Proceeds - The net proceeds from the offering will be used for working capital and other general corporate purposes [2]. Regulatory Information - The securities are being offered under a registration statement on Form S-3, which was declared effective by the SEC on December 6, 2022 [3]. - A prospectus supplement will be filed with the SEC regarding the securities being offered [3]. Product Information - Lucid's EsoGuard® Esophageal DNA Test is designed for early detection of esophageal precancer in at-risk patients, utilizing a noninvasive office procedure with the EsoCheck® Esophageal Cell Collection Device [5].